| Full text | |
| Author(s): Show less - |
Bazotte, Roberto Barbosa
[1]
;
Hirabara, Sandro Massao
[2]
;
Duarte Serdan, Tamires Afonso
[2]
;
Gritte, Raquel Bragante
[2]
;
Souza-Siqueira, Talita
[2]
;
Gorjao, Renata
[2]
;
Masi, Laureane Nunes
[2]
;
Antunes, Marina Masetto
[1]
;
Cruzat, Vinicius
[3]
;
Pithon-Curi, Tania Cristina
[2]
;
Curi, Rui
[2]
Total Authors: 11
|
| Affiliation: | [1] Univ Estadual Maringa, Dept Pharmacol & Therapeut, Maringa, PR - Brazil
[2] Univ Cruzeiro Sul, Interdisciplinary Postgrad Program Hlth Sci, Sao Paulo, SP - Brazil
[3] Torrens Univ Australia, Fac Hlth, Melbourne, Vic - Australia
Total Affiliations: 3
|
| Document type: | Review article |
| Source: | BIOMEDICINE & PHARMACOTHERAPY; v. 135, MAR 2021. |
| Web of Science Citations: | 0 |
| Abstract | |
In 1918, quinine was used as one of the unscientifically based treatments against the H1N1 virus during the Spanish flu pandemic. Originally, quinine was extracted from the bark of Chinchona trees by South American natives of the Amazon forest, and it has been used to treat fever since the seventeenth century. The recent COVID-19 pandemic caused by Sars-Cov-2 infection has forced researchers to search for ways to prevent and treat this disease. Based on the antiviral potential of two 4-aminoquinoline compounds derived from quinine, known as chloroquine (CQ) and hydroxychloroquine (HCQ), clinical investigations for treating COVID-19 are being conducted worldwide. However, there are some discrepancies among the clinical trial outcomes.Thus, even after one hundred years of quinine use during the Spanish flu pandemic, the antiviral properties promoted by 4aminoquinoline compounds remain unclear. The underlying molecular mechanisms by which CQ and HCQ inhibit viral replication open up the possibility of developing novel analogs of these drugs to combat COVID-19 and other viruses. (AU) | |
| FAPESP's process: | 19/25936-5 - Research Contingency Fund for Institutional Infraestructure of the Cruzeiro do Sul University - 2019 |
| Grantee: | Tania Cristina Pithon Curi |
| Support Opportunities: | Research Grants - Technical Reserve for Institutional Research Infrastructure |
| FAPESP's process: | 18/09868-7 - Cellular and molecular mechanisms of insulin resistance and inflammation in obese Wistar rats and lean Goto-Kakizaki rats: causes and associations with diet and physical exercise |
| Grantee: | Rui Curi |
| Support Opportunities: | Research Projects - Thematic Grants |